Track topics on Twitter Track topics that are important to you
Adoptive cell transfer (ACT) is a promising immunotherapeutic approach for cancer treatment. During ACT, if a patient is subjected to lymphodepletion prior to cell transfer, there is an observed improvement in a patient’s response to treatment. However, lymphodepletion is associated with detrimental effects, including severe immune dysfunction that persists after treatment.
Researchers at the National Cancer Institute (NCI) have developed a technology that provides formulations and dosage protocols for administration of hetIL-15 to replace lymphodepletion in ACT. Administration of hetIL-15 may not only replace lymphodepletion in ACT, it may also increase ACT efficiency due to its ability to increase lymphocyte growth, differentiation, and tumor entry. NCI’s technology provides specific dosage and treatment schedules of hetIL-15 to improve tumor entry and increase and maintain the number of tumor-specific lymphocytes in the tumor with an acceptable toxicity profile. Therefore, administration of hetIL-15 with ACT can replace lymphodepletion in cancer immunotherapy protocols. Thus, the NCI’s cancer immunotherapeutic protocol replicates the advantages of lymphodepletion preconditioning of the host for successful ACT while avoiding the adverse effects associated with lymphodepletion.
Ng SSM, et al.
Ng S, et al. Heterodimeric IL-15 enhances tumor infiltration, persistence and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA.
Researchers at the NCI seek licensing and/or co-development research collaborations for methods of performing adoptive cell transfer by administering a heterodimeric IL-15/IL-15 receptor alpha complex (hetIL-15) in the absence of lymphodepletion.
Original Article: Use of Heterodimeric IL-15 in Adoptive Cell TransferNEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...